🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
530,76 USD
Máx. histórico
558,88
4 días
Split 2:1 del 24/08/2000
Caída desde máximo
-5,03%
Rango 52 semanas
403,16 – 568,67
Variación hoy
-4,05%
Cierre anterior
553,15
Rango de hoy
529,15 – 561,96
Volumen hoy
2.372.462
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 30,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 576,29 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 11 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 21/01/1994 | 9,25 | 9,63 | 9,25 | 9,25 | +1,37% | 4,05% | 38.800 |
| 20/01/1994 | 9,25 | 9,25 | 9,00 | 9,13 | +0,69% | 2,70% | 17.600 |
| 19/01/1994 | 9,00 | 9,25 | 9,00 | 9,06 | -2,03% | 2,78% | 77.200 |
| 18/01/1994 | 8,75 | 9,25 | 8,63 | 9,25 | +2,78% | 7,14% | 109.400 |
| 17/01/1994 | 9,50 | 9,50 | 9,00 | 9,00 | -4,64% | 5,26% | 57.400 |
| 14/01/1994 | 9,38 | 9,50 | 9,13 | 9,44 | +3,42% | 4,00% | 40.200 |
| 13/01/1994 | 9,13 | 9,38 | 9,13 | 9,13 | -1,35% | 2,74% | 130.400 |
| 12/01/1994 | 9,50 | 9,50 | 9,25 | 9,25 | -2,63% | 2,63% | 125.000 |
| 11/01/1994 | 9,75 | 9,75 | 9,25 | 9,50 | -1,30% | 5,13% | 108.000 |
| 10/01/1994 | 9,63 | 9,88 | 9,38 | 9,63 | +0,00% | 5,19% | 73.600 |
| 07/01/1994 | 9,88 | 10,00 | 9,63 | 9,63 | +0,00% | 3,80% | 266.600 |
| 06/01/1994 | 9,25 | 9,75 | 9,00 | 9,63 | +6,94% | 8,11% | 560.600 |
| 05/01/1994 | 9,00 | 9,25 | 9,00 | 9,00 | +0,00% | 2,78% | 229.800 |
| 04/01/1994 | 9,00 | 9,25 | 9,00 | 9,00 | -0,69% | 2,78% | 26.600 |
| 03/01/1994 | 9,13 | 9,25 | 9,00 | 9,06 | -2,03% | 2,74% | 131.800 |
| 31/12/1993 | 8,75 | 9,25 | 8,63 | 9,25 | +7,25% | 7,14% | 151.200 |
| 30/12/1993 | 8,75 | 8,75 | 8,50 | 8,63 | -0,72% | 2,86% | 14.000 |
| 29/12/1993 | 8,56 | 8,75 | 8,38 | 8,69 | +0,72% | 4,38% | 87.400 |
| 28/12/1993 | 8,38 | 8,75 | 8,38 | 8,63 | +1,47% | 4,48% | 202.600 |
| 27/12/1993 | 8,63 | 8,63 | 8,25 | 8,50 | +1,49% | 4,35% | 18.000 |
| 23/12/1993 | 8,25 | 8,63 | 8,25 | 8,38 | -2,90% | 4,55% | 81.800 |
| 22/12/1993 | 8,25 | 8,63 | 8,25 | 8,63 | +2,99% | 4,55% | 43.000 |
| 21/12/1993 | 8,63 | 8,63 | 8,25 | 8,38 | +0,00% | 4,35% | 85.000 |
| 20/12/1993 | 8,63 | 8,63 | 8,38 | 8,38 | +0,00% | 2,90% | 107.600 |
| 17/12/1993 | 8,63 | 8,75 | 8,25 | 8,38 | -4,29% | 5,80% | 359.400 |
| 16/12/1993 | 8,00 | 9,00 | 7,75 | 8,75 | +12,90% | 15,63% | 815.400 |
| 15/12/1993 | 7,75 | 8,00 | 7,75 | 7,75 | -3,13% | 3,23% | 27.200 |
| 14/12/1993 | 8,00 | 8,25 | 7,75 | 8,00 | +0,00% | 6,25% | 85.800 |
| 13/12/1993 | 8,25 | 8,25 | 7,88 | 8,00 | +1,59% | 4,55% | 18.400 |
| 10/12/1993 | 7,50 | 8,25 | 7,50 | 7,88 | +0,00% | 10,00% | 114.600 |